Search PubMedSearch

PubMed · 2780098

[Roxithromycin passage in the cervix mucus].

Abstract

We studied the diffusion of roxithromycin in the cervix mucus of fifteen healthy normal women, aged 24 to 44 (median 37). They were consulting physician to have an IUD. After this intervention (between the 4 to 7 days of menstrual cycle) they received an antibiotic treatment with the standard dose of roxithromycin: 150 mg bd for a week. At the end of this treatment the cervix mucus was taken 1 to 12 hours after the last antibiotic dose. We dose the roxithromycin by a microbial assay (Bacillus subtilis ATCC 6633, antibiotic medium 1, pH 8) and the acid alpha-1-glycoprotein by an immunodiffusion assay. All women had drug measurable with levels from 0.45 to 2.07 mg/l (median: 0.80 mg/l). The acid alpha-1-glycoprotein levels were quite constant (median: 0.19 mg/l). The antibiotic concentrations observed are above the MIC of the major genital pathogens, mainly C. trachomatis, G. vaginalis, H. ducreyi and U. urealyticum, but lower than the MIC ov N. gonorrhoeae and M. hominis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Mounier, P Renaudie, J Baudet, F Denis. 1989. [Roxithromycin passage in the cervix mucus].. https://pubmed.ncbi.nlm.nih.gov/2780098/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence.

PURPOSE: We evaluated the efficacy and safety of yohimbine and isoxsuprine or pentoxifylline in the management of vasculogenic erectile dysfunction. MATERIALS AND METHODS: A total of 20 patients diagnosed with arterial insufficiency and cavernous venous leakage by pharmacological penile duplex scanning underwent nonhormonal oral therapy. A randomized crossover study was performed using 5.4 mg. yohimbine plus 10 mg. isoxsuprine or 400 mg. pentoxifylline 3 times daily. Response to therapy was assessed by a sexual questionnaire and repeat penile duplex ultrasonography. RESULTS: No patient in either phase of the study in either group had a complete response to the oral regimen(s) and there was no improvement in the pre-injection or post-injection cavernous arterial peak systolic flow velocities or resistance indexes. CONCLUSIONS: Our study suggests that these oral agents, although well tolerated, were not effective in the management of these patients with mixed vasculogenic erectile dysfunction.

Administration, Oral